![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 18, 15579-15585, May 3, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, July 23, 2001, and in revised form, February 7, 2002
Several phosphorylations are known to occur in
the N-terminal transactivation domain of human p53. To explore the
structural effects of these phosphorylations, we have chemically
synthesized the unphosphorylated p53-(1-39) and its three
phosphorylated analogs, phosphorylated at Ser-15, Thr-18, and Ser-20.
p53-(1-39) and its Ser-15 and Thr-18 phosphorylated analogs were
tested for interaction with p300. The order of binding affinities was
similar to that derived from biochemical experiments with the whole
protein, indicating functional integrity of the domain. Differences in
chemical shifts and coupling constants indicate significant structural
changes upon phosphorylations. The single tryptophan in the
unphosphorylated domain has an emission maximum and a Stern-Volmer
constant that are characteristics of tryptophans situated in protein
interiors. The diffusion constant is monomer-like, with an axial ratio
of 1:7.5, indicating a significant degree of compaction. Upon
phosphorylations, the emission maximum and diffusion constant change
significantly toward values that indicate more open conformations.
Binding of the hydrophobic probe bis-1-anilino-8-naphthalenesulfonate
to the unphosphorylated and one of the phosphorylated domains is also
significantly different, suggesting different conformations. We propose
that phosphorylations switch the largely folded transactivation domain to more open conformations that interact with transcription factors such as p300/cAMP- responsive element-binding protein-binding protein, leading to enhancement of gene expression.
p53 lies at the center of the cellular response to
genotoxic stress. Various stress signals integrate by means of
post-translational modifications of the p53 protein, resulting in
different downstream responses (1). A major response is to halt cell
cycle progression with corresponding activation of genes needed for DNA
repair. A second kind of response is apoptosis (2). Genotoxic stresses activate many cellular kinases that phosphorylate various serine and
threonine residues in p53, as well as enzymes that cause lysine acetylations (3). Presently, at least 12 serine/threonines and 2 lysines are known to be modified in p53 and there may be more
modification sites. This signaling system and the code of post-translational modification are still incompletely understood (1).
An understanding of the structural basis of such signal integration and
transduction remains a distant dream.
p53 is a multidomain protein. The N-terminal domain 1-73 is
responsible for transactivation function and binding of such proteins as Mdm2/Hdm2, which down-regulate the levels of p53 (4). The N-terminal
domain of p53 is emerging as one of the most important regions in p53
function. One of the major pathways of transactivation is through
interaction with p300/CBP1
and recruitment of this protein to the required promoter region. p300/CBP has well known histone acetyltransferase activity, which results in histone acetylation and remodeling of the chromosome in that
region leading to enhanced transcription (5). Clearly, interactions of
the N-terminal domain of p53 with Mdm2 and p300/CBP and possibly with
other regulatory proteins are of crucial importance in understanding
the various roles played by p53 as the guardian of the genome.
Although crystal or NMR structures of other domains have been reported
(6, 7), very little is known about the structure of this important
domain. Only very recently, an NMR study of this domain has shown this
to be disordered, although the authors concluded that secondary
structural elements are present (8). It now appears that there are at
least eight phosphorylation sites within the N-terminal subdomain:
serines 6, 9, 15, 20, 33, 37, and 46 and threonine 18 (1). Functions of
several of these phosphorylations are not clear. However, it appears
that the Ser-15 phosphorylation plays a crucial role in the
transactivation process (9-11). Phosphorylation of Ser-15 occurs very
soon after initial stressing of the cells (12). Among other things,
this phosphorylation leads to phosphorylation of the Thr-18 by casein
kinase-1 (13) and consequent inhibition of interaction of p53 with Mdm2
(14). Ser-15 phosphorylation also leads to greatly increased binding of
p53 to CBP/p300. It is also possible that the phosphorylation of Ser-15
leads to an enhancement of acetylation of C-terminal lysines and has
some effect on p53 mediated apoptosis (15). Such multiple effects of a
single phosphorylation suggest that this phosphorylation may be causing
a conformational change in the transactivation domain of the protein.
Similarly, phosphorylation at Ser-20 has been implicated in various
downstream responses (10, 16, 17).
In this study we have focused our attention on the structural
consequences of the phosphorylation of Ser-15, Thr-18, and Ser-20 in
the N-terminal domain. Because it is difficult to produce specifically phosphorylated derivatives of the whole protein, we have chosen to
study the N-terminal subdomain 1-39, which can be chemically synthesized in phosphorylated forms in large quantities.
Materials
Fmoc amino acids were purchased from Novabiochem (San Diego,
CA). Vydac C-8 column was purchased from Grace-Vydac (Hesperia, CA).
All other materials were of high quality analytical grade.
Methods
Expression and Purification of p300--
His6-tagged
recombinant full-length p300 was expressed in Sf21 insect cells
by using the baculovirus expression system and purified by
nickel-nitrilotriacetic acid affinity purification as described
previously (18). Briefly, Sf21 cells were infected with the
recombinant baculovirus for 72 h, following which they were
harvested and homogenized in a homogenization buffer (10 mM
Tris-HCl, pH 7.5, containing 10% glycerol, 0.1% Nonidet P-40, 2 mM Peptide Synthesis and Characterization--
The p53-(1-39)
peptide and its phosphorylated derivatives were synthesized by the
solid phase method with Fmoc chemistry using a model 430A peptide
synthesizer (Applied Biosystems, Foster City, CA). Phosphoserine was
incorporated as Fmoc-Ser(PO(OBzl)OH)-OH, and phosphothreonine was
incorporated as Fmoc-Thr(PO(OBzl)OH)-OH. Peptides were cleaved from the
resin, and side-chain protecting groups were removed by incubating in
reagent K (trifluoroacetic acid:phenol:thioanisole:H2O:ethanedithiol, 82.5:5:5:5:2.5)
for 3 h at room temperature. The p53-(1-39) peptide and its
phosphorylated derivatives were purified by HPLC on a pH-stable Vydac
C-8 column with 0.2% hexafluoroacetone-NH4OH, pH 7.0, acetonitrile. The masses of peptides were confirmed by matrix-assisted
laser desorption ionization time-of-flight mass spectrometry on a
Voyager PR-HR (PerSeptive Biosystems, Framingham, MA).
Another truncated version of p53, Pep53-(17-28) and a variant (Bpep53;
see below for the sequence) were synthesized in a Biolynx 4175-peptide
synthesizer using Fmoc protocol. Amino acids, except those stated
below, were used as N-terminal Fmoc-protected and C-terminally
pentafluorophenyl ester-activated with
N-hydroxybenzotriazole. NMR Spectroscopy--
All NMR spectra were taken in a Bruker
DRX-500 NMR spectrometer equipped with a Z-field gradient
probe. All measurements were done in high precision 5-mm NMR tubes in
10 mM phosphate buffer, pH 7.0, containing 100 mM NaCl in 90% H2O and 10% D2O.
All NMR experiments were done at 27 °C, unless stated otherwise.
TOCSY and NOESY spectra were measured using standard pulse sequences in
the Bruker pulse library using WATERGATE water suppression method. The
diffusion measurements were carried out by stimulated echo-based pulse
sequence (90° gradient pulse, 90° delay for diffusion, 90°
gradient pulse acquisition). Typical delay for diffusion was set at 200 ms (202.244 (= Circular Dichroism--
CD spectra were measured in a Jasco
J-700 spectropolarimeter in 10 mM phosphate buffer, pH 7, containing 100 mM NaCl. The cuvette path length was 2 mm.
Temperature was 7.5 °C. The bandwidth was 2 nm, and scan speed was
20 nm/min.
Fluorescence Measurements--
All fluorescence spectra were
measured in a Hitachi F-3010 fluorescence spectrophotometer at ambient
temperature (25 ± 1 °C), unless stated otherwise. Acrylamide
quenching was done in 10 mM phosphate buffer, pH 7, containing 100 mM NaCl. The observed fluorescence values
were corrected for volume change and inner filter effect. Inner filter
effect was corrected using the formula Fcorr = Fobs × antilog[(Aex + Aem)/2]. The excitation wavelength was 295 nm, and the emission wavelength was 340 nm. Excitation and emission band
passes were 5 nm each. The quenching data was fitted to the Stern-Volmer equation: F0/F = 1 + Ksv[Q], where
F0 is the fluorescence intensity at zero
quencher concentration, F is the intensity at a given
quencher concentration Q, and Ksv is
the Stern-Volmer constant.
Bis-ANS binding was carried out in 10 mM phosphate buffer,
pH 7.0, containing 100 mM NaCl. Excitation and emission
band passes were set to 5 nm. 10 µM p53-(1-39) or Ser20P
was titrated with increasing concentrations of bis-ANS, and
fluorescence intensity at 490 nm was recorded. The excitation
wavelength was 387 nm. Fluorescence intensities were corrected for
volume changes and inner filter effect.
Interaction of p53-(1-39) Domain and Its Derivatives with
p300--
Ser15P was labeled with fluorescein isothiocyanate at low pH
so that the modification may be primarily directed toward the N
terminus (resulting from lower pK of the Because we have attempted to work with the isolated p53-(1-39)
fragment, it is important to assess the structural and functional integrity of this isolated domain. The functional integrity of the
1-39 domain can be judged from its interaction with the natural receptors, e.g. TAF, Mdm2, or p300 (23). Previous reports
have suggested that this domain binds to TAF and Mdm2 with high
affinity (14, 24, 25). In addition, we have measured the binding of the
1-39 domain of p53 and two of its phosphorylated derivatives with
p300. We have used fluoresceinated Ser15P peptide to measure binding by
fluorescence anisotropy. Fig.
1A shows the titration of
fluoresceinated Ser15P with increasing concentrations of p300. Anisotropy increased and then quickly saturated. When the data were
fitted to a single-site binding equation, a dissociation constant of 81 nM was obtained. A qualitative estimate of binding constants of Thr18P and p53-(1-39) was obtained using competition with
these unlabeled fragments. Fig. 1 (B and C) shows
the decrease in anisotropy when a complex of p300 and fluoresceinated
Ser15P, 360 nM each, was titrated with increasing
concentrations of either unlabeled Thr18P or p53-(1-39). In the case
of Thr18P, the anisotropy decreased very rapidly and returned to the
value of the free Ser15P peptide when the concentration reached 1:1
stoichiometry with p300. This suggests total displacement of the Ser15P
peptide from the complex by an equal concentration of Thr18P. This
indicates a much higher binding affinity of Thr18P as compared with
Ser15P with p300. On the other hand, p53-(1-39) only weakly displaced Ser15P from the p300 complex. Even a 10-fold molar excess was not able
to displace it fully (displacement may be only 50%, as can be
estimated from anisotropy value), indicating at least severalfold weaker affinity. Two papers have attempted to estimate binding affinities of phosphorylated p53 protein (21, 23). It appears that
Ser-15 phosphorylated p53 binds much more tightly than the unphosphorylated one and Thr18P also binds very tightly compared with
Ser15P. Thus, the isolated 1-39 domain faithfully reproduces the
functional nature of the protein, indicating retention of functional
integrity.
To find out if there were significant structural differences between
p53-(1-39) fragment and the 1-73 domain, chemical shifts of both
these fragments were compared (8). Almost complete assignment of
unmodified p53-(1-39) fragment was made using standard two-dimensional
homonuclear NOESY/TOCSY strategy (26). The chemical shift differences
of the amide protons are shown in Fig.
2A. The differences are
largely confined to the N- and C-terminal ends. The difference at the
C-terminal end is readily reconcilable, as the 1-39 fragment contains
a free
Effect of Phosphorylation on the Structure and Fold of
Transactivation Domain of p53*
§,
§,
,
**,
,
§§, and
**¶¶
Department of Biophysics, Bose Institute,
P-1/12 C. I. T., Scheme VII M, Calcutta 700 054, India,
the ¶ Laboratory of Structure-Function Biochemistry, Department of
Chemistry, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, and the 
Transcription and Disease
Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru
Center for Advanced Scientific Research, Jakkur,
Bangalore 560064, India
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES
-mercaptoethanol, 2 mM
phenylmethylsulfonyl fluoride, 50 µg/ml leupeptin, 50 µg/ml
aprotinin, 500 mM NaCl, and 15 mM imidazole). The cleared lysate was bound to the nickel-nitrilotriacetic
acid-agarose beads (Qiagen GmbH) and washed in the same buffer with 300 mM NaCl and 15 mM imidazole. The protein was
eluted in the homogenization buffer containing 200 mM NaCl
and 250 mM imidazole. The purified protein showed a single
band upon Coomassie stain and Western blot. It was also fully
functional by histone acetyltransferase assay.
-Aminoisobutyric acid (Aib), Asp,
and Thr were used in the COOH form using
benzotriazole-1-yloxytrispyrrolidinophosphonium hexafluorophosphate as
activating agent with N-hydroxybenzotriazole and
N,N-diisopropyl ethylamine (1:1:2). The peptides were
acetylated at the N terminus using acetic anhydride and triethylamine
(1:1) and cleaved from the resin (Novasyn KA) with trifluoroacetic
acid:ethanedithiol:anisole:phenol (94:2:2:2, v/v/v/w). Both the
peptides were purified by reverse phase HPLC on C-18 (Waters
Associates) column using 0-60% acetonitrile in 0.1% trifluoroacetic
acid and characterized by NMR. The sequences of the two peptides are
ETFSDLWKLLPE (Pep53) and BTFBDBWKBLBE (Bpep53), where B stands for
Aib.
in the equation below) ms counting finite length of
the pulses) (19). The strength of the gradient (G) pulse was
varied, and G2 versus ln[intensity]
was plotted. The strength of the gradient and the intensity are related
by the following equation.
I is the intensity,
(Eq. 1)
is the gyromagnetic ratio,
D is the diffusion constant,
is the delay between the
first two 90° pulses,
is the delay between two gradient pulses
(includes delay for diffusion), and G is the strength of the
gradient pulse. From the slope of the line, D can be
calculated, because all other parameters are known.
D20,w values were calculated
according to Cantor and Schimmel (20). Perrin factors and hydrodynamic radii were calculated from diffusion constants according to Cantor and
Schimmel (20). The temperature was 27 °C.
JNH-
H values were derived from double
quantum-filtered COSY spectra according to Kim and Prestegard (21).
-amino group
(Ref. 22)). 7.7 µM Ser15P was mixed with 20-fold molar
excess of fluorescein isothiocyanate in 5% v/v ethanol (final
concentration) in 0.2 M potassium phosphate, pH 6.0, at
25 °C, with continuous stirring for 4 h. It was then
centrifuged, and the supernatant was loaded on to a Sephadex G-25
column, equilibrated, and eluted with 20 mM Tris-HCl, pH
7.9, containing 100 mM KCl. For direct titration, 720 nM fluorescein-labeled Ser15P in 20 mM Tris-HCl
buffer, pH 7.9, containing 100 mM KCl was titrated with
p300, and the anisotropy was determined at each point. The excitation
wavelength was 480 nm, and the emission wavelength was 520 nm. For the
competition experiments, 360 nM labeled Ser15P was mixed
with 360 nM p300 in 20 mM Tris-HCl, pH 7.9, containing 100 mM KCl buffer and incubated for 5 min. This
buffer was different from the buffer used for other spectroscopic
experiments, as p300 is known to be stable in this buffer. The
anisotropy was then determined, followed by addition of increasing
amounts of unlabeled competing peptide. The excitation and emission
wavelengths were 480 and 520 nm, respectively. The excitation and
emission band passes were 10 and 5 nm, respectively. Anisotropy
(A) was calculated according to the following formula: A = (I
I
)/(I
+ 2I
),
where I
is the fluorescence intensity with
parallel polarizers (0/0) and I
is the fluorescence intensity with crossed polarizers (0/90).
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSION
REFERENCES

View larger version (20K):
[in a new window]
Fig. 1.
Binding of p300 with different phosphorylated
derivatives of p53-(1-39). A, titration of
fluoresceinated Ser15P at a concentration of 720 nM with
increasing concentrations of p300. The line shown is the
best fit to a single-site binding equation. B, titration of
360 nM fluorescein-labeled Ser15P and 360 nM
p300 complex with increasing concentrations of Thr18P and p53-(1-39)
(C). Lines in B and C are
merely polynomials and do not represent any binding equation. The
solution conditions were 20 mM Tris-HCl, pH 7.9, containing
100 mM KCl. The temperature was 25 ± 1 °C.
Excitation and emission wavelengths were 480 and 520 nm, respectively.
The error bars are derived from three independent
measurements. For clarity only every third error
bar is shown.
-carboxyl group whereas the 1-73 fragment consists of
continuing peptide chain. The difference in the N terminus is likely to
arise from the additional residues and N-terminal modification of the
recombinant protein (8). Only two residues, 16 and 28, in the middle
showed greater than 0.1 ppm difference in chemical shifts. The
implications of this observation are not clear, although indirect
effects of extra residues in the N terminus cannot be completely ruled
out. Thus, clearly the 1-39 fragment is similar to the 1-73 domain in
structure and it is unlikely that the 1-39 subdomain has any strong
interaction with the rest of the domain.

View larger version (24K):
[in a new window]
Fig. 2.
Comparison of chemical shifts of
amide protons of different p53 N-terminal domains. A,
chemical shift difference of p53-(1-39) domain and recombinant
p53-(1-73) domain at 5 °C. Chemical shifts of p53-(1-73) domain
were taken directly from Lee et al. (6). p53-(1-39)
chemical shifts were obtained from TOCSY spectra using water as
standard. Chemical shift differences between the unphosphorylated
p53-(1-39) domain and three phosphorylated derivatives: Ser15P
(B), Thr18P (C), and Ser20P (D). The
chemical shifts were obtained from standard NOESY/TOCSY assignment
procedure at 27 °C. All the spectra were taken in 10 mM
phosphate buffer, pH 7.0, containing 100 mM NaCl. Seven
prolines are not shown for obvious reasons. Several resonances have
zero chemical shift differences and hence do not appear as a
bar in the figure.
Chemical shifts can also be used to compare structural differences between the phosphorylated and unphosphorylated domains. We have compared the chemical shifts of amide resonances of the unphosphorylated and three phosphorylated domains. Fig. 2 (B-D) shows the chemical shift differences for amide protons between p53-(1-39) and Ser15P, Thr18P, and Ser20P, respectively. In all three cases, the largest difference was seen for the phosphorylated Ser/Thr residue, as expected. In case of Thr18P, very significant shift was also observed for the proximal residues, Phe19 and Ser-20. Interestingly, relatively large shifts were seen for some residues, which are distant from the phosphorylation site. This distant effect was found in all three phosphorylated domains, but appeared to be more pronounced in Thr18P and Ser20P. Glu-28, Ser-37, Gln-38, and Ala-39 showed changes of chemical shift greater than 0.1 ppm. In the case of Ser20P, modest chemical shift changes were seen throughout residues 21-30. All the residues were fairly distant from the modification site, suggesting long range interactions present in the domain. In particular, the residues at the C-terminal end, Ser-37, Gln-38, and Ala-39, are so distant from the phosphorylation site that secondary structure-mediated change can be ruled out.
Another parameter that may reflect conformational change is the
coupling constant between NH and C
H
(JNH-
H). This coupling constant tends to have
a low value (~4-5 Hz) when the Ramachandran angle (
) is in the
helical range and a high value (~8-9 Hz) when the Ramachandran angle
is in the extended conformation range. Thus, for relatively mobile
peptide chains, perhaps lacking a unique conformation, a change in the
value of JNH-
H may be a reflection of a
change in the distribution among different conformations. Fig.
3 shows the difference of
JNH-
H values between p53-(1-39) and Ser15P
and Ser20P. It is clear that relatively large changes (~2 Hz) in the
value of JNH-
H occurred. The changes appear to be confined to the central part of the molecule (between residues 16-28) and the C-terminal residues. This pattern is very similar to
the changes in the chemical shift, supporting long distance structural
changes upon phosphorylation.
|
From a number of studies, it is now well established that tryptophan
fluorescence in proteins is a sensitive probe of folding and tertiary
structure (27). A number of fluorescence properties are sensitive to
environment and solvent accessibility, two of which are fluorescence
emission maximum and Stern-Volmer constant for collisional quenching.
To assess the folded nature of the domain, we have measured
fluorescence properties of the only tryptophan present at position 23. This is in the central part of the helix that spans the residues 17-26
(6) and is close to many of the phosphorylation sites in this domain.
It is an important determinant for the Mdm2 interaction and possibly
the p300/CBP interaction (4, 28). Thus, environment of this tryptophan
residue may shed light on many important aspects of structure and
function of this domain. The emission maxima of the unphosphorylated
p53-(1-39) and Ser15P, Thr18P, and Ser20P are 341, 343, 350, and 350 nm, respectively (Table I). Fig.
4 shows the acrylamide quenching pattern
(Stern-Volmer plots) for all the above mentioned domains. It is clear
that the plots are linear in most cases and can be fitted well to a
Stern-Volmer equation with a single class of fluorophore.
Ksv (Stern-Volmer constant) of the domains are
3.9, 8.0, 11.0, and 11.2 M
1 for
unphosphorylated, Ser15P, Thr18P, and Ser20P, respectively. As a
control we have determined the Ksv values of a
peptide consisting of residues 17-28 (Pep53) and the same peptide with
five Aib substitutions (Bpep53). Aib substitutions were made to
predispose the peptide into a more helical conformation. CD and NMR
spectra indicate that Bpep53 is in a helical conformation (data not
shown). In both the above mentioned peptides, the Stern-Volmer
constants are high, 15.3 and 19.7 M
1 for
Pep53 and Bpep53, respectively. The emission maxima are ~350 nm in
both cases. Clearly, the Ksv of the tryptophan
undergoes a dramatic reduction in going from Pep53, a largely random
coil, to p53-(1-39). Even induction of helix by insertion of Aib does not reduce the Ksv or shift the emission
maximum. Thus, the blue-shifted emission maximum in the p53-(1-39)
fragment and lowering of Ksv may be the result
of long range interactions. The long range interactions result in a
folded conformation, which shields Trp-23 from solvent. Change in the
Ksv value upon phosphorylation suggests a change in environment, and the corresponding red shift of emission maximum suggests that this change leads to an increased exposure of Trp-23. Properties of all the domains are summarized in Table I. Interestingly, for p53-(1-39), the Stern-Volmer plot is somewhat nonlinear, perhaps indicating the presence of multiple conformations. The inset
shows the emission maximum shift as a function of increasing acrylamide concentrations for p53-(1-39). The shift of emission maximum for a
single tryptophan protein (without tyrosine as well) strongly supports
presence of multiple conformations for the p53-(1-39). For the other
phosphorylated fragments, no significant emission maximum shift could
be detected (data not shown).
|
|
Pulse field gradients NMR can be used to measure translational
diffusion constants, which are directly related to the hydrodynamic properties (29). Translational diffusion constants thus can be used to
measure hydrodynamic properties of the transactivation domain and its
phosphorylated derivatives, which in turn may shed some light on the
compactness of the domains and states of aggregation. Fig.
5 shows the G2
versus ln[intensity] plots for the unphosphorylated and
the three phosphorylated domains. All the diffusion constants are
summarized in Table II. The translational
diffusion constant at 20 °C
(D20,w) of the unphosphorylated
p53-(1-39) is 1.31 × 10
6 cm2
s
1. This value is between that of sucrose and
ribonuclease A and consistent with a monomer of molecular mass of 4.35 kDa (30). The compactness of the domain can be gauged from the fact
that an unstructured 13-residue peptide has nearly the same diffusion constant and hydrodynamic radius (31) (1.54 × 10
6
cm2 s
1; see below for the axial ratios).
Thus, the stabilization of the tertiary structure in the 1-39 domain
is likely to be from intramolecular interactions rather than
intermolecular ones. The Ser-15 phosphorylated domain has a diffusion
constant of 1.21 × 10
6 cm2
s
1, ~8% lower than the unphosphorylated one. The
Thr18P diffusion constant is also similar (1.22-1.27 × 10
6 cm2 s
1) as is the diffusion
constant for Ser20P (1.19-1.24 × 10
6
cm2 s
1), all significantly different from the
unphosphorylated case. Determination of diffusion constants at
different concentrations does not show any significant change or
trends, indicating that no significant aggregation occurs. This
indicates that, upon phosphorylation, the compactness of the 1-39
domain is partially lost. If one assumes average hydration (0.34 g of
water/g of protein) and partial specific volume (0.73 cm3/g), one can qualitatively evaluate the shape of the
protein through the Perrin factor, F (30). Table I lists the
Perrin factors and the axial ratios of the corresponding ellipsoids.
For the unphosphorylated 1-39 domain, the ratio is ~1:7.5 (for
prolate as well as oblate ellipsoids) indicating a nonspherical shape.
In contrast, a completely unstructured 13-residue peptide gave an axial
ratio value of ~1:20 by the same technique (31). A much longer
peptide chain, such as p53 transactivation domain, if completely
disordered, should give even higher axial ratios. Thus, we may conclude
that p53-(1-39) has a folded conformation to some degree.
Phosphorylations increase the axial ratio. This indicates a more open
conformation of the phosphorylated domains.
|
|
To assess the secondary structural content of the domain in the
phosphorylated and unphosphorylated states, we have measured the far-UV
CD spectra. Small peptides display considerable flexibility and
predisposition only to certain conformations. To accentuate the
conformational preferences, peptide CD spectra are often taken at lower
temperatures. Hence, we have measured CD spectra at 7.5 °C. Fig.
6 shows the CD spectra of the
unphosphorylated and Ser-15 phosphorylated p53-(1-39). The CD spectrum
of the unphosphorylated domain exhibits small but significant mean
residue ellipticity at 222 nm and a pronounced minimum around 200 nm.
Considering that the solution conformation of the domain to be an
equilibrium mixture of
-helix (characterized by a double minima at
208 and 222 nm) and an extended conformation (characterized by a
pronounced minimum at 190 nm), the CD spectrum of the unphosphorylated
domain suggests the presence of some fraction of helical population. Upon phosphorylation, the absolute CD intensity decreases slightly but
with no change in spectral shape, indicating very little change in
secondary structure. The other two phosphorylated domains show Ser15P
like CD spectra under similar conditions (data not shown). Interestingly, the peptide Pep53 has no significant negative band at
222 nm and its CD spectrum resembles that of an extended conformation. Previous NMR studies have suggested that the domain 1-73 contains a
helix spanning residues 17-26 (6). This is consistent with significant
helical content of the fragment p53-(1-39). The lack of any
significant helical content of the peptide Pep53 may therefore suggest
the presence of long range interactions in the 1-39 domain that
stabilizes the helix.
|
Bis-ANS is widely used as a probe for hydrophobic regions of proteins.
The general experience with bis-ANS and ANS is that they are incapable
of binding to completely unfolded states. This is evident from no
detectable binding to proteins at conditions that completely unfold the
proteins (32). The hydrophobic patches in proteins that are thought to
be important for binding of this class of fluorescent probes require
some organized structure to bring hydrophobic elements in a protein
chain in close proximity. We have thus probed organized structure using
bis-ANS binding as a probe in p53-(1-39) and its Ser-20 phosphorylated
counterpart. Fig. 7 shows the binding
isotherms. It is clear that Ser20P is almost identical to the buffer
control suggesting no binding. On the other hand, there is a
significant additional fluorescence enhancement with p53-(1-39). This
provides additional support that the unphosphorylated domain has some
elements of a folded structure, which disappears or reduces upon
phosphorylation.
|
The presence of long range interactions in the transactivation domain
of p53 raises an interesting question about its nature. The NMR study
indicated that the central helix extends up to residue Leu-26 (6). The
stretch of four contiguous residues (PENN) that follow the helix has a
high probability of turn formation. A search for such a sequence
(LPENNV) through Protein Data Bank revealed five proteins that have
such a sequence with only one sequence mutation. In all such cases, the
residues adopt a turn conformation (Protein Data Bank identification
codes 1cpb, 1f4b, 1js4, 1sky, and 1ehi). If the residues LPENNV adopt a
turn in the p53 transactivation domain, several C-terminal residues may
interact with residues at the N-terminal side of the domain. This is
consistent with the observation that the last three residues show
significant chemical shift change upon phosphorylation that appears to
result in a more open structure. Why the phosphorylations lead to more
open states is not known at present. However, in Thr18P, the hydroxyl
group of Thr-18 may hydrogen-bond to NH or to the
-COOH group of
Asp-21, contributing to the stability of the helix. Phosphorylation
would eliminate such hydrogen bonds and in addition would cause charge
repulsion, destabilizing the helix.
One of the general mechanisms of transcription activation in eukaryotes is by acetylation of histones and consequent increased accessibility of the DNA toward proteins that includes the transcription initiation machinery (33, 34). One of the functions of the transcription activation factors such as p53 is to localize itself in an appropriate region through sequence-specific DNA binding activity and recruit a histone acetyltransferase such as p300/CBP in the locality (35). How this recruitment occurs is not well understood in terms of structural or energetics principles. Activation of p53 in response to genotoxic stress results in transcription activation from a number of promoters. The N-terminal domain of p53 is the domain responsible for interaction with p300/CBP and its recruitment (36). It has been suggested that the strength of interaction between the transactivation domain and its partners correlates with the degree of transcription activation (37). In case of Ser15P, it has been shown that phosphorylation leads to enhanced interaction with CBP (28). The structural basis of this enhanced interaction remains unclear.
Many transactivation domains are known to be acidic and flexible (38).
Flexibility implies a rapidly interconverting distribution of states.
However, little is known about their structures. The p53
transactivation domain falls into this general category. Recently, NMR
studies have indicated that this domain has defined secondary structures. Based on lack of long range nuclear Overhauser effects, it
was suggested that the domain lacks organized tertiary structure (8).
Fluorescence results and hydrodynamic properties reported here,
however, argue for presence of long range interactions and a folded
structure. Change of chemical shifts of residues distant from the
phosphorylation sites also argues in favor of long range interactions.
We believe that lack of long range nuclear Overhauser effects results
from the flexible nature of the domain and a consequent reduction of
correlation time rather than an unfolded conformation. Flexibility is
also known in other domains. It has been argued that such flexible
structures allow those domains to fit into "molds" of different
receptor structures (39). This increase in ability to recognize
different targets comes at a cost of binding affinity as the entropic
barrier for a disorder-order transition has to be overcome. A similar
argument can be advanced here. We propose that the flexible
transactivation domain of p53 is composed of rapidly equilibrating
conformers, one quasi-globular and the others relatively open. We have
observed that fluorescence quenching of p53-(1-39) leads
to significant blue shift of the emission maximum, suggesting multiple
environments for the single tryptophan residue. It has been proposed
that transactivation domains interact with multiple partners through
semispecific hydrophobic regions (37). In case of p53, the central
helix appears to be the critical interaction point (40). In a folded
structure, where the helix may be partially shielded, the interaction
energy with the partner proteins may be reduced. Phosphorylations at
different positions shift the equilibrium toward the open forms to
various degrees, causing enhancement of protein-protein interaction.
| |
CONCLUSION |
|---|
|
|
|---|
By several techniques we have shown that the transactivation
domain of p53 has a folded structure. It is likely that this folded
structure is mobile and lacks organized tertiary interactions. Folded
structures without organized tertiary interactions are well known in
proteins, of which molten globules are the most ubiquitous. Such
dynamic folded structures may be important for proteins that interact
with multiple receptors.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge the help of Dr. Soumen Basak and Jaganmoy Guin for the measurement of CD spectra and the help of Barun Mazumdar for the measurement of NMR spectra. We also thank Asim Banerjee for help with HPLC. Dr. Kundu thanks L. Kraus and J. T. Kadonaga for the baculovirus expression vector.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Nissan Science Foundation and a grant-in-aid for scientific research (to K. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Recipient of a Council of Scientific and Industrial Research, India (CSIR) junior research fellowship.
Permanent address: Dept. of Chemistry, St. Xaviers College,
Calcutta 700016, India.
** Recipient of a grant from the Department of Atomic Energy, Government of India.
§§ Recipient of a grant from CSIR.
¶¶ To whom correspondence should be addressed. Tel.: 91-33-412-1261; Fax: 91-33-334-3886; E-mail: sidroy@vsnl.com or sidroy@ boseinst.ernet.in.
Published, JBC Papers in Press, February 19, 2002, DOI 10.1074/jbc.M106915200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
CBP, cAMP-responsive
element-binding protein-binding protein;
Pep53, peptide corresponding
to residues 17-28 of human p53;
Bpep53, same peptide as Pep53 except
five
-aminoisobutyric acid residues incorporated in designated
positions;
Aib,
-aminoisobutyric acid;
Ser15P, p53-(1-39) domain
phosphorylated at serine 15;
Thr18P, p53-(1-39) domain phosphorylated
at threonine 18;
Ser20P, p53-(1-39) domain phosphorylated at serine
20;
Fmoc, fluorenyl methoxycarbamoyl;
D20, w, diffusion constant at 20 °C
in water;
ANS, 1-anilino-8-naphthalenesulfonate;
HPLC, high performance
liquid chromatography;
TOCSY, total correlation spectroscopy;
NOESY, nuclear Overhauser effect spectroscopy.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Appella, E.,
and Anderson, C. W.
(2000)
Pathol. Biol. (Paris)
48,
227-245[Medline]
[Order article via Infotrieve] |
| 2. | Puri, P. L., Maclachlan, T. K., Levero, M., and Giordano, A. (1999) in The Molecular Basis of Cell Cycle and Growth Control (Stein, G. S. , Baserga, R. , Giordano, A. , and Denhardt, D. T., eds) , pp. 15-79, Wiley-Liss, New York |
| 3. |
Ljungman, M.
(2000)
Neoplasia
2,
208-225[Medline]
[Order article via Infotrieve] |
| 4. |
Kussie, P. H.,
Gorina, S.,
Marechal, V.,
Elenbaas, B.,
Moreau, J.,
Levine, A. J.,
and Pavletich, N. P.
(1996)
Science
274,
948-953 |
| 5. |
Sterner, D. E.,
and Berger, S. L.
(2000)
Microbiol. Mol. Biol. Rev.
64,
435-459 |
| 6. |
Jeffrey, P. D.,
Gorina, S.,
and Pavletich, N. P.
(1995)
Science
267,
1498-1502 |
| 7. |
Rustandi, R. R.,
Baldisseri, D. M.,
and Weber, D. J.
(2000)
Nat. Struct. Biol.
7,
570-574[CrossRef][Medline]
[Order article via Infotrieve] |
| 8. |
Lee, H.,
Mok, K. H.,
Muhandiram, R.,
Park, K. H.,
Suk, J. E.,
Kim, D. H.,
Chang, J.,
Sung, Y. C.,
Choi, K. Y.,
and Han, K. H.
(2000)
J. Biol. Chem.
275,
29426-29432 |
| 9. |
Stewart, Z. A.,
Tang, L. J.,
and Pietenpol, J. A.
(2001)
Oncogene
20,
113-124[CrossRef][Medline]
[Order article via Infotrieve] |
| 10. |
Damia, G.,
Filiberti, L.,
Vikhanskaya, F.,
Carrassa, L.,
Taya, Y.,
D'incalci, M.,
and Broggini, M.
(2001)
Neoplasia
3,
10-16[CrossRef][Medline]
[Order article via Infotrieve] |
| 11. |
Bean, L. J.,
and Stark, G. R.
(2001)
Oncogene
20,
1076-1084[CrossRef][Medline]
[Order article via Infotrieve] |
| 12. |
She, Q. B.,
Chen, N.,
and Dong, Z.
(2000)
J. Biol. Chem.
275,
20444-20449 |
| 13. |
Dumaz, N.,
Milne, D. M.,
and Meek, D. W.
(1999)
FEBS Lett.
463,
312-316[CrossRef][Medline]
[Order article via Infotrieve] |
| 14. |
Sakaguchi, K.,
Saito, S.,
Higashimoto, Y.,
Roy, S.,
Anderson, C. W.,
and Appella, E.
(2000)
J. Biol. Chem.
275,
9278-9283 |
| 15. |
Unger, T.,
Sionov, R. V.,
Moallem, E.,
Yee, C. L.,
Howley, P. M.,
Oren, M.,
and Haupt, Y.
(1999)
Oncogene
18,
3205-3212[CrossRef][Medline]
[Order article via Infotrieve] |
| 16. |
Jabbur, J. R.,
Huang, P.,
and Zhang, W.
(2000)
Oncogene
19,
6203-6208[CrossRef][Medline]
[Order article via Infotrieve] |
| 17. |
Chehab, N. H.,
Malikzay, A.,
Stavridi, E. S.,
and Halazonetis, T. D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13777-13782 |
| 18. |
Kraus, W. L.,
and Kadonaga, J. T.
(1998)
Genes Dev.
12,
331-342 |
| 19. | Canet, D. (1996) Nuclear Magnetic Resonance: Concepts and Methods , John Wiley & Sons, New York |
| 20. | Cantor, C. R., and Schimmel, P. R. (1980) Biophysical Chemistry , Vol. II , p. 584, W. H. Freeman & Co., San Francisco |
| 21. |
Kim, Y.,
and Prestegard, J. H.
(1990)
Proteins
8,
377-385[CrossRef][Medline]
[Order article via Infotrieve] |
| 22. |
Garel, J. R.
(1976)
Eur. J. Biochem.
70,
179-189[Medline]
[Order article via Infotrieve] |
| 23. |
Sakaguchi, K.,
Herrera, J. E.,
Saito, S.,
Miki, T.,
Bustin, M.,
Vassilev, A.,
Anderson, C. W.,
and Appella, E.
(1998)
Genes Dev.
12,
2831-2841 |
| 24. |
Uesugi, M.,
and Verdine, G. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14801-14806 |
| 25. |
Dornan, D.,
and Hupp, T. R.
(2001)
EMBO Rep.
2,
139-144[CrossRef][Medline]
[Order article via Infotrieve] |
| 26. | Wuthrich, K. (1986) NMR of Proteins and Nucleic Acids , John Wiley & Sons, New York |
| 27. | Lakowicz, J. R. (1999) Principles of Fluorescence Spectroscopy , 2nd Ed. , Kluwer Academic/Plenum Publishers, New York |
| 28. |
Gu, W.,
Shi, X. L.,
and Roeder, R. G.
(1997)
Nature
387,
819-823[CrossRef][Medline]
[Order article via Infotrieve] |
| 29. |
Wilkins, D. K.,
Grimshaw, S. B.,
Receveur, V.,
Dobson, C. M.,
Jones, J. A.,
and Smith, L. J.
(1999)
Biochemistry
38,
16424-16431[CrossRef][Medline]
[Order article via Infotrieve] |
| 30. | Cantor, C. R., and Schimmel, P. R. (1980) Biophysical Chemistry , 1st Ed., Vol. II , W. H. Freeman & Co., San Francisco |
| 31. |
Pal, D.,
Mahapatra, P.,
Manna, T.,
Chakrabarti, P.,
Bhattacharyya, B.,
Banerjee, A.,
Basu, G.,
and Roy, S.
(2001)
Biochemistry
40,
15512-15519[CrossRef][Medline]
[Order article via Infotrieve] |
| 32. |
Das, B. K.,
Bhattacharyya, T.,
and Roy, S.
(1995)
Biochemistry
34,
5242-5247[CrossRef][Medline]
[Order article via Infotrieve] |
| 33. |
Nakayama, T.,
and Takami, Y.
(2001)
J. Biochem. (Tokyo)
129,
491-499 |
| 34. |
Davie, J. R.,
and Moniwa, M.
(2000)
Crit. Rev. Eukaryot. Gene Exp.
10,
303-325[Medline]
[Order article via Infotrieve] |
| 35. |
Ptashne, M.,
and Gann, A.
(1997)
Nature
386,
569-577[CrossRef][Medline]
[Order article via Infotrieve] |
| 36. |
Grossman, S. R.
(2001)
Eur. J. Biochem.
268,
2773-2778[Medline]
[Order article via Infotrieve] |
| 37. |
Melcher, K.
(2000)
J. Mol. Biol.
301,
1097-1112[CrossRef][Medline]
[Order article via Infotrieve] |
| 38. |
Nagadoi, A.,
Nakazawa, K.,
Uda, H.,
Okuno, K.,
Maekawa, T.,
Ishii, S.,
and Nishimura, Y.
(1999)
J. Mol. Biol.
287,
593-607[CrossRef][Medline]
[Order article via Infotrieve] |
| 39. |
Kriwacki, R. W.,
Hengst, L.,
Tennant, L.,
Reed, S. I.,
and Wright, P. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11504-11509 |
| 40. |
Gu, W.,
and Roeder, R. G.
(1997)
Cell
90,
595-606[CrossRef][Medline]
[Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. S. El-Dahr, K. Aboudehen, and S. Dipp Bradykinin B2 receptor null mice harboring a Ser23-to-Ala substitution in the p53 gene are protected from renal dysgenesis Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1404 - F1413. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Ou, P.-H. Chung, T.-P. Sun, and S.-Y. Shieh p53 C-Terminal Phosphorylation by CHK1 and CHK2 Participates in the Regulation of DNA-Damage-induced C-Terminal Acetylation Mol. Biol. Cell, April 1, 2005; 16(4): 1684 - 1695. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Knights, Y. Liu, E. Appella, and M. Kulesz-Martin Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification J. Biol. Chem., December 26, 2003; 278(52): 52890 - 52900. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||